of reactive oxygen species, pyroptosis, angiogenesis, and, consequently, tissue remodeling and repair. [1] [2] [3] [4] There are four main groups of pattern recognition receptors, ie, Toll-like receptors, NOD-like receptors, C-type lectin receptors, and RIG-I-like receptors, and genes encoding them are broadly expressed, eg, in epithelial cells, endothelial cells, keratinocytes, lymphocytes, granulocytes, fibroblasts, and neurons. [1] [2] [3] [4] A summary of the most modern conceptual data about members of these groups and about their structure and function can be obtained from recent comprehensive reviews by Kawai and Akira, 1 Elinav et al, 2 Osorio et al, 3 and Loo and Gale. 4 The completion of the human genome project and widespread distribution of genotyping technologies have led to an enormous number of studies devoted to associating inherited gene polymorphisms with various diseases. Single nucleotide polymorphisms may result in amino acid substitutions altering protein function or splicing, and they can also change the structure of enhancer sequences during splicing 5 and affect mRNA stability. 6 Single nucleotide polymorphisms may alter transcription factor binding motifs, change the efficacy of enhancer or repressor elements, 7 and alter the structure of translation initiation codons that may lead to downregulation of wild-type transcripts. 8 Gene polymorphisms located in leucine-rich repeats constituting ectodomains of many pattern recognition receptors may affect the ability of these receptors to bind pathogens they normally recognize, 9 single nucleotide polymorphisms in transmembrane domains can lead to defects of intracellular receptor transport that prevent receptors localizing to the cell membrane, 10 and, finally, polymorphisms in the cytosolic domains may result in altered interactions with adaptor proteins or in disrupted receptor dimerization. Therefore, there are many avenues by which single nucleotide polymorphisms may alter pattern recognition receptor expression and activity. Because pattern recognition receptors recognize a number of oncogenic infectious agents and launch an immune response against them, inherited variation in their structure may modulate cancer risk and, possibly, influence cancer progression. In addition, pattern recognition receptors bind a lot of endogenous ligands, [1] [2] [3] [4] so polymorphisms of genes encoding them can affect risk and/or progression of some autoimmune disorders and, consequently, cancer risk and/or progression, given that there is a fundamental and epidemiological association between many autoimmune diseases and cancer risk.
The problem
Although there are a lot of studies investigating the association between single nucleotide polymorphisms in genes encoding Toll-like receptors and NOD-like receptors and the risk and features of cancer progression, there is an almost complete absence of articles analyzing the correlation between polymorphisms of genes encoding C-type lectin receptors and RIG-I-like receptors and cancer risk or progression. This can be explained by the fact that the first wave of studies devoted to the association of polymorphisms of genes encoding Toll-like receptors and NOD-like receptors with cancer risk appeared only in 2004, and the number of such papers was relatively small until 2008. In addition, known hypotheses about the infectious agents causing human cancer and their recognition by pattern recognition receptors suggested that Toll-like receptors and NOD-like receptors should play a major role in the immune response against biological carcinogens. However, more recent findings concerning specific potentially carcinogenic ligands of C-type lectin receptors and RIG-I-like receptors were only obtained in the last few years, 3,4 so there has not been enough time as yet to conduct comprehensive investigations between single nucleotide polymorphisms of genes encoding C-type lectin receptors and RIG-I-like receptors and cancer risk.
However, there is some evidence supporting the hypothesis that inherited features of C-type lectin receptor and RIG-I-like receptor structure can be associated with increased cancer risk.
First premise: specific ligands
Certain C-type lectin receptors and RIG-I-like receptors recognize PAMPs of oncogenic infectious agents. 3, 4, 11, 12 C-type lectin receptors: 11, 12 it is possible to suggest that risk of lung cancer may be modulated by polymorphisms of the MRC1, CD209, CLEC7A, CLEC6A, and CLEC4E genes, oral cancer risk by single nucleotide polymorphisms of the MRC1, CD207, CD209, CLEC6A, and CLEC4E genes, risk of glioblastoma and colorectal cancer by polymorphisms of the CD209 gene, hepatocellular carcinoma risk by polymorphisms of the CD209 and RIG-I genes, and risk of lymphoma, multiple myeloma, nasopharyngeal carcinoma, and esophageal and gastric cancer by single nucleotide polymorphisms of the RIG-I gene. In addition, single nucleotide polymorphisms of MRC1, CD207, LY75, CD209, CLEC1B, and CLEC4A genes may correlate with cancer types associated with HIV-1 infection.
Second premise: polymorphisms affecting function
Certain polymorphisms of genes indicated above may have functional consequences on the molecular level that can lead to association of such single nucleotide polymorphisms with risk or progression of some diseases that may modulate cancer risk, so these gene polymorphisms may affect cancer risk indirectly. In addition, polymorphisms of these genes correlating with diseases that are not related to cancer risk may also be useful in oncogenomics because they may have functional consequences at the molecular level as well, although they have not been investigated in relation to association with cancer risk or progression.
For instance, it was suggested that variant alleles of MRC1 rs2477637, rs2253120, rs2477664, rs692527, rs1926736, and rs691005 gene polymorphisms are associated with development of asthma 13 (eg, variant A allele of rs1926736 was connected with decreased asthma risk). In addition, Alter et al 14 found that the variant A allele (S396) of rs1926736 (G396S) polymorphism is associated with a lower leprosy risk and, conversely, G allele (G396) correlates with increased risk of this disease. Interestingly, G396 did not influence leprosy risk in combination with T399 and L407 (amino acids resulting from variant alleles of rs2478577 and rs2437257, respectively). 14 The authors noted that all three of these MRC1 gene single nucleotide polymorphisms map to the second C-type lectin domain (CTLD2) of the MRC1 protein, with their in vitro results suggesting that a direct interaction between CTLD2 and an accessory receptor molecule is necessary in order for microbial ligand recognition to occur.
14 It is logical to propose that such interaction would be sensitive to G396 only in the context of the A399-F407 haplotype, and not in the context of the T399-L407 haplotype.
14 Thus, rs1926736 may have substantial functional consequences at the molecular level, but this depends on its relationship with other single nucleotide polymorphisms in the same exon. Finally, Hattori et al 15 showed that a variant allele of rs691005 polymorphism, located within the 3′ untranslated region of the MRC1 gene, is associated with a higher risk of sarcoidosis. Because of its location, it is feasible that this single nucleotide polymorphism may alter the regulatory binding sequence and influence mRNA expression. 15 The only study investigating the association of polymorphisms of genes encoding C-type lectin receptors and RIG-I-like receptors with cancer risk is a study by Xu et al. 16 They investigated single nucleotide polymorphisms of the CD209 gene and found that the GG genotype of the rs2287886, AA genotype of the −939 promoter polymorphism, and the G allele of the rs735239 single nucleotide polymorphism were connected with higher nasopharyngeal carcinoma risk. 16 Polymorphisms in the promoter of the CD209 gene and in the CD209 gene were also associated with hemorrhage in patients with dengue fever (G allele of rs4804803), 17, 18 modulated tuberculosis risk (G allele of rs4804803, A allele of rs735239), [19] [20] [21] higher celiac disease risk in HLA-DQ2-negative cases (G allele of rs4804803), 22 increased ulcerative colitis risk in HLA-DR3-positive patients (G allele of rs4804803), 23 higher susceptibility to cytomegalovirus infection (G allele of rs735240 and C allele of rs2287886), 24 protection from lung cavitation 20 and fever during tuberculosis 25 (GG genotype and G allele of rs4804803), decreased HIV-1 infection risk (GG genotype of rs4804803), 21 accelerated progression to acquired immune deficiency syndrome in HIV-1-infected hemophiliacs (C allele of rs2287886), 26 decreased human T-lymphotropic virus type I infection risk (G allele of rs4804803, A allele of rs2287886), 27 increased severity of liver disease during hepatitis C virus infection (G allele of rs4804803), 28 and better prognosis following severe acute respiratory syndrome (G allele of rs4804803). 29, 30 It was shown that the A allele of the rs4804803 single nucleotide polymorphism may increase gene expression in vitro, 17 Abbreviations: SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; MRC, mannose receptor C; CD, cluster of differentiation; NPC, nasopharyngeal carcinoma; DC-SIGN, dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin; TNF, tumor necrosis factor; IL, interleukin; IP, interferon-gamma inducible protein 10; HIV, human immunodeficiency virus; AIDS, acquired immunodeficiency virus; HTLV, human T-cell lymphotropic virus; HCV, hepatitis C virus; SARS, severe acute respiratory syndrome; LDH, lactate dehydrogenase; Sp, specificity protein; AP, activator protein; CLEC, C-type lectin domain, the next number is the family number 7, the next letter is the letter of family member; TLR, toll-like receptor; PBMC, peripheral blood mononuclear cell; IFN, interferon; RIG-I, retinoic acid-inducible gene I; GM-CSF, granulocyte-macrophage colony-stimulating factor; MAvS/vISA/IPS-1, mitochondrial antiviral signaling protein/virus-induced signaling adapter/induced by phosphate starvation-1; NF-κB, necrosis factor kappa B; RANTES, regulated on activation, normal T-cell expressed and secreted; TRAF, TNF receptor-associated factor; SLE, systemic lupus erythematosus.
expression in subjects with the G allele may result in an impaired immune response against hepatitis C virus, 28 M. tuberculosis, 19, 21 and bacteria potentially causing celiac disease 22 and ulcerative colitis, 23 that elevates the risk of diseases caused by these infectious agents. Such a decreased immune response may protect from hemorrhage during dengue fever, 17 from lung cavitation, 20 from fever during tuberculosis, 25 and from lung injury during severe acute respiratory syndrome 29, 30 as a result of less cytokine production and diminished activation of immune cells. However, from the point of view of Vannberg et al, 20 conversely, lower CD209 gene expression as a consequence of G allele of rs4804803 polymorphism may protect against tuberculosis because of decreased production of proinflammatory cytokines such as interleukin-4. Further fundamental, translational, and clinical studies are necessary to clarify these discrepancies. Nevertheless, although there are a number of reasons for the discrepancies between studies devoted to the association between CD209 single nucleotide polymorphisms and development of tuberculosis, but confounding host, bacterial, and submit your manuscript | www.dovepress.com Dovepress Dovepress environmental factors between different study populations should be taken into account. In addition, Mezger et al 24 demonstrated that alleles of rs735240 and rs2287886 polymorphisms may also influence CD209 gene expression and thus affect transcription factor binding.
In relation to the CLEC7A (Dectin-1) gene, it was also found that a variant allele of rs16910526 polymorphism is associated with impaired cytokine production by macrophages 31, 32 and with a defective response to Aspergillus and Candida invasion. 33, 34 The variant S form of I223S polymorphism was characterized by a lower capacity of the receptor to bind zymosan. 35 Among polymorphisms of genes encoding RIG-Ilike receptors, RIG-I single nucleotide polymorphisms are the most investigated. Pothlichet et al 36 conducted a comprehensive study investigating the functional consequences of rs36055726 (P229fs) and rs11795404 (S183I) polymorphisms. They found that the variant allele of rs36055726 results in a truncated constitutively active RIG-I (that leads to permanent production of proinflammatory mediators, particularly antiviral), and, conversely, the variant allele of rs11795404 induces an abortive conformation of RIG-I, causing formation of unintended stable complexes between CARD modules of RIG-I and between RIG-I and its downstream adapter protein, MAVS, rendering RIG-I incapable of downstream signaling and further cytokine synthesis. 36 Moreover, Shigemoto et al identified a variant of rs11795404 as a loss-of-function allele. 37 Ovsyannikova et al 38, 39 showed that a minor allele of rs10813831 polymorphism is associated with a decrease in the rubella virus-specific granulocyte-macrophage colony-stimulating factor/interleukin-6/IgG response, whilst a variant allele of rs3824456 is connected with an increase in the rubella virusspecific tumor necrosis factor alpha response, and a variant allele of rs669260 correlates with an increase in the rubellaspecific antibody level. Hu et al 40 discovered that a variant allele of rs10813831 polymorphism leads to increased gene expression and, consequently, cytokine production due to an amino acid substitution in the CARD domain of RIG-I that results in functional alteration of this RIG-I-like receptor.
There are also a lot of studies investigating the role of IFIH1/MDA5 (the gene encoding MDA5 protein that is also a RIG-I-like receptor) single nucleotide polymorphisms in the etiology of autoimmune diseases, but almost all of them are devoted to type 1 diabetes and multiple sclerosis, and data about the association of these diseases with cancer risk are conflicting, in that some studies showed an increased risk in patients with type 1 diabetes and multiple sclerosis, 41, 42 and in other investigations no connection or decreased risk of cancer has been observed. [43] [44] [45] [46] [47] [48] [49] Taking into account that there are no carcinogenic infectious agents recognizing MDA5, it does not seem to be prudent to investigate IFIH1/MDA5 gene polymorphisms from the oncogenomic point of view. In addition, polymorphisms of genes coding for components of the Toll-like receptor signaling pathway may modulate cancer risk as single nucleotide polymorphisms of the TLR gene family. 1 The same statement can be true for C-type lectin receptor and RIG-I-like receptor signaling pathways. For instance, a variant allele of rs11905552, encoding MAVS/ VISA/IPS-1, a key downstream signaling molecule of RIG-I and MDA5, was associated with a particular systemic lupus erythematosus phenotype. 50 It was found that this single nucleotide polymorphism leads to reduced production of type I interferon and other proinflammatory mediators, and also to the absence of anti-RNA-binding protein autoantibodies. 50 In addition, variant alleles of rs17857295 and rs2326369 polymorphisms of the MAVS/VISA/IPS-1 gene were associated with nephritis and arthritis in patients suffering from systemic lupus erythematosus. 51 A variant allele of another single nucleotide polymorphism of this gene, rs7269320, showed associations with different clinical characteristics of this autoimmune disease. 51 All the population case-control studies mentioned above are summarized in Table 1 .
Conclusion and future directions
All polymorphisms of genes encoding C-type lectin receptors, RIG-I-like receptors, and proteins of their specific signaling pathways that have known functional consequences and may be relevant to oncogenomics are summarized in Table 2 . The fundamental basis for the association of the inherited coding variation in genes encoding C-type lectin receptors and RIG-I-like receptors with cancer is represented by the defects in the immune response (that are caused by various single nucleotide polymorphisms) against specific carcinogenic infectious agents. Some polymorphisms may be valued as the most promising for further oncogenomic investigations on the basis of their association with cancer risk or because of their substantial functional consequences on the molecular level according to the following concept:
Gene polymorphism may be included on the short list for further oncogenomic studies if:
• The single nucleotide polymorphism leads to substantial functional consequences at the molecular level (for instance, it strongly affects transcription, splicing, translation, stability and transport of pre-mRNA, mRNA, noncoding RNA, or protein encoding by the gene, or it noticeably influences signaling of synthesized protein) • It is associated with risk of cancer in population studies • It has functional consequences at the molecular level and it is strongly associated with a condition that significantly increases the risk of cancer (threshold may vary for each cancer type) The gene polymorphism can be also included on the extended list if:
• It is characterized by more subtle functional alterations in a gene that, nonetheless, result in qualitative or quantitative alterations of the encoding protein (or noncoding RNA) • It is associated with a condition that substantially increases the risk of cancer but has not specifically been identified to increase the risk of cancer. According to this concept, the indicated short list of polymorphisms includes rs1926736, rs2478577, rs2437257, rs691005 (all located in the MRC1 gene), rs2287886, -939 promoter polymorphism, rs735239, rs735240, rs4804803 (all located in the CD209 gene), rs16910526 (CLEC7A gene), and rs36055726, rs11795404, rs10813831 (all located in the RIG-I gene). Other polymorphisms mentioned in this article may be added to the extended list for further investigations. Polymorphisms with known functional effects (rs1926736, rs2437257, rs691005, rs2287886, rs735240, rs4804803, rs16910526) were associated with relatively significant modulation of risk of diseases (as shown in Table 1 ) which is logical and demonstrates the correctness of the studies in which functional consequences of such single nucleotide polymorphisms were analyzed. There are still no comprehensive functional investigations for other single nucleotide polymorphisms correlated with risk of disease, so it is difficult to conclude which of them have independent significance, and which of them are just in linkage disequilibrium with truly functional variants.
In addition, PAMPs of specific infectious agents recognized by each C-type lectin receptor or RIG-I-like receptor define cancer types which can be primarily associated with inherited structural variation in the receptors discussed earlier. Furthermore, if a single nucleotide polymorphism of a gene encoding a specific C-type lectin receptor or RIG-I-like receptor is associated with risk or progression features of certain malignancies, polymorphisms in genes encoding specific signaling molecules constituting pathways of these receptors should correlate with similar neoplasms, if they have substantial functional consequences at the molecular level. The issue of an association of single nucleotide polymorphisms of genes encoding C-type lectin receptors, RIG-I-like receptors, and proteins of pattern recognition receptor pathways with various features of cancer progression is open, and only further population studies would be likely to give a definite answer.
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Reasons for discrepancies in different investigations analyzing the association of polymorphisms in genes encoding C-type lectin receptors, RIG-I-like receptors, and the proteins of their signaling pathways with various aspects of cancer development may include confounding host, bacterial, or environmental factors in different ethnicities modulating penetrance of variant alleles and affecting the risk of conditions increasing cancer risk (such as autoimmune diseases, precancerous gastric lesions, tuberculosis, recurrent pneumonia), different bacterial impact on the etiology of such conditions in different populations (that will be reflected in different features of C-type lectin receptor/ RIG-I-like receptor-mediated immune response because of specific C-type lectin receptor/RIG-I-like receptor-ligand interaction), differences in sample size, in clinicopathological characteristics between study samples, in prevalence of infectious agents in case and control groups, diagnostics, stratification, genotyping methods, and chance.
Another interesting issue is that associations between single nucleotide polymorphisms of genes encoding C-type lectin receptors and RIG-I-like receptors and cancer risk can be skewed by differences between cohorts in various immune responses and infections that may not influence cancer development. The problem is that the design in an epidemiological study having a large sample is very seldom ideal. Stratification by status of chronic infection is rather difficult because of their extreme diversity and because of the very high cost of such testing. Stratification by an immune response is even more complex because of innumerable peculiarities in functioning of the immune system. Therefore, if the study has a perfect funding source, stratification by infection status can be possible, but stratification by immune response status will be far from ideal.
Unfortunately, to the best of the authors' knowledge, no genome-wide association studies of the connection between polymorphisms of genes encoding the C-type lectin receptor and RIG-I-like receptors and cancer risk or progression have been performed, and this can be explained by the relative newness of the problem or perhaps by another unknown reason.
Summing up, polymorphisms of genes encoding C-type lectin receptors, RIG-I-like receptors, and proteins of their signaling pathways may be promising targets for oncogenomics and possibly could be used in programs of cancer prevention and early cancer diagnostics in the future. Population and further fundamental studies devoted to their association with cancer risk of progression should shed light on this issue.
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